宫颈鳞癌Ⅲ期同步放化疗后巩固化疗疗效分析

目的]探讨宫颈鳞癌Ⅲ期患者同步放化疗后巩固化疗的疗效和毒副作用.方法]将2007年1月至2008年6月收治的84例宫颈鳞癌Ⅲ期同步放化疗的患者随机分为试验组（40例）和对照组（44例）,试验组患者在同步化疗后接受2个疗程的巩固化疗.对照组未行巩固化疗.观察比较两组患者的3年生存率和毒副反应.结果]试验组和对照组相比,3年生存率（86.5%和72.7%）和无进展生存率（82.0%和70.3%）均有所提高,差异有统计学意义（P＜0.05）.试验组Ⅲ～Ⅳ度骨髓抑制发生率为27%.结论]宫颈鳞癌Ⅲ期同步放化疗后巩固化疗对生存率有益,但骨髓抑制较为严重.

Analysis of the Efficacy of Consolidation Chemotherapy after Concurrent Chemoradiation for the Treatment of Stage III Cervical Squamous Cell Carcinoma

Objective]To explore the efficacy and toxicity of consolidation chemotherapy after concurrent chemoradiotherapy for the treatment of stage Ⅲ cervical squamous cell carcinoma. Methods] Totally 84 patients with stage Ⅲ cervical squamous cell carcinoma receiving concurrent chemoradiotherapy admitted to our hospital from Jan. 2007 to June 2008 were randomly divided into experiment group（ n = 40） and control group（ n = 40）. The 3-year survival rate and toxicity of two groups were compared. Results]Compared with control group, the 3-year overall survival （OS） and progression-free survival（PFS） rate of consolidation group increased（86. 5% vs 72. 7%, 82. 0% vs 70.3 % ）, and there was significant difference（ P %0.05）. However, the incidence of grade Ⅲ OR Ⅳ of bone marrow suppression in consolidation group was higher than that in control group. Conclusion]Consolidation chemotherapy after concurrent chemoradiation for the treatment of stage Ⅲ cervical squamous cell carcinoma is benefit for the survival rate, but has more serious bone marrow suppression.